Vol. XXIX, n.3, 2008 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Editors-in-Chief
A. Onnis
Montréal (CND)
P. Bösze
Budapest (Hungary)


Associate Editors
M. Marchetti
Montréal (CND)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Barber H.K., New York, NY (USA)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M., Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,Athens (Greece)
Jordan J.A., Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Kudelka A.P., Houston, TX (USA)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H., London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Vîrtej P., Bucharest (Romania)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXIX, n. 3, 2008
 
   
CONTENTS  
DISTINGUISHED EXPERT SERIES  
New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors 205
K. Syrjänen - Turku, FINLAND
Novel observations on risk factors that are still controversial (i.e., oral contraception, smoking) or not previously studied (drug addiction), reproductive factors as potential cofactors of HPV infections in cervical carcinogenesis (i.e., menarche, menopause), and finally on the performance of different optional screening strategies among younger and older women are discussed.
 
 
ORIGINAL ARTICLES  
Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma (LAUCC): Kitasato Gynecologic Radiation Oncology Group (KGROG 0501) - initial analysis 222
Y. Niibe, S. Tsunoda, T. Jobo, M. Imai, K. Matsuo, K. Matsunaga, N. Unno, K. Hayakawa - Nagoya, JAPAN
The phase II study of concurrent chemoradiotherapy using nedaplatin for LAUCC is reported.
 
Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries 225
B. Rash, P. Martin-Hirsch, A. Schneider, M. Sideri, J. Tan, A. Torné, B. Standaert - Rixensart, BELGIUM
Resource use and costs associated with the management of abnormal pap smears vary between countries, depending on the screening programme and the histological type.
 
Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry 233
J. Luo, J.H. Qian, J.K. Yu, S. Zheng, X. Xie, W.G. Lu - Hangzhou, CHINA
The combination of SELDI and laser capture microdissection (LCM) is effective in finding the key molecules in ovarian tumorigenesis.
 
Sentinel lymph nodes in endometrial cancer: is hysteroscopic injection valid? 239
D. Clement, A.S. Bats, N. Ghazzar-Pierquet, M.A. Le Frere Belda, F. Larousserie, C. Nos, F. Lecuru - Paris, FRANCE
Hysteroscopic peritumoral radiotracer injection for detecting sentinel lymph nodes (SLNs) in patients with endometrial cancer is described together with the evaluation of the resulting SLN detection rate.
 
Interval debulking in epithelial ovarian carcinomas: the past, present and the future 242
M. Gultekin, K. Diribas, E. Buru, P. Dursun, K. Yuce, A. Ayhan - Ankara, TURKEY
The approach to interval debulking surgery in ovarian carcer is discussed in relation to neo-adjuvant chemotherapy and compared with the literature data.
 
Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas 246
P.L. Sung,Y.J. Chen, R.S. Liu, H.J. Shieh, P.H. Wang, M.S. Yen, K.C. Wen, S.H. Shen, C.R. Lai, C.C. Yuan - Taipei, TAIWAN
The use of F-18-fluorodeoxyglucose positron emission tomography (18-FDG PET) for post-therapy surveillance of uterine sarcoma is described.
 
Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study 252
K. Niwa, K. Onogi,Y.Wu, H. Mori, R.C. Harrigan, T. Tamaya - Gifu-city, USA
MPA with chemotherapy might improve the prognosis of advanced epithelial ovarian cancers.
 
Synchronous ovarian and endometrial carcinoma: a strong link to endometriosis? 256
A. Kondi-Pafiti, D. Grapsa, A. Liapis, K. Papadias, E. Kairi-Vassilatou, D. Hasiakos - Athens, GREECE
A clinicopathological study of synchronous ovarian and endometrial carcinomas reveals a strong link to endometriosis.
 
Prognostic factors in patients with carcinoma of the vulva - our own experience and literature review 260
P. Blecharz, K. Karolewski, T. Bieda, M. Klimek, J. Pudelek, E. Kojs, K. Zur, P. Dzialak, K. Urbanski - Krakow, POLAND
Evaluation of prognostic factors and treatment outcomes in patients with vulvar cancer are examined.
 
KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature 264
M. Zafrakas, T.D. Theodoridis, L. Zepiridis, I.D. Venizelos, T. Agorastos, J. Bontis - Thessaloniki, GREECE
KIT expression was analyzed immunohistochemically in primary uterine sarcomas and was found to be very weak in the majority of tumors.
 
Cl-channel blockers inhibit cell proliferation and arrest the cell cycle of human ovarian cancer cells 267
M. Li, B. Wang,W. Lin - Jinan, CHINA
The role of chloride channels in cell proliferation and cell cycles of human ovarian cancer cell A2780 was investigated.
 
 
CASE REPORTS  
Cervical cancer associated with genital prolapse - a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient 272
D. Reimer, A. Sztankay, I. Steppan, E. Abfalter, H. Lunzer, C. Marth, A.G. Zeimet - Innsbruck, AUSTRIA
Successful treatment of cervical cancer associated with procidentia by external brachytherapy and extracorporeal HDR-AL with concomitant chemotherapy followed by surgery.
 
Stage 1B cervical cancer in a pregnant woman at 25 weeks of gestation 276
E. González Bosquet, A. Castillo, M. Medina, M. Suñol, A. Capdevila, J.M. Lailla - Barcelona, SPAIN
A case of a 28-year-old pregnant woman diagnosed with Stage 1B cervical cancer is described.
 
The role of ovarian transposition in patients with early stage cervical cancer - two case reports 280
N. Salakos, K. Bakalianou, C. Iavazzo, G. Paltoglou, K. Papadias, A. Liapis, A. Kondi-Pafiti - Athens, GREECE
The role of ovarian transposition in patients with early-stage cervical cancer is examined.
 
Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9 282
D.T. Arioz, C. Tokyol, F.K. Sahin, G. Koker, S. Yilmaz, M. Yilmazer, S. Ozalp - Eskisehir, TURKEY
A very rare case of squamous cell carcinoma arising in a mature cystic teratoma in a 31-year-old single woman with very high levels of CA19-9 and normal levels of CEA is presented.
 
Primary vaginal melanoma: a case report and literature review 285
M. Schmidt, A. Honig, M. Schwab, P. Adam, J. Dietl - Wuerzburg, GERMANY
Vaginal melanoma is a rare malignancy. Among different treatment options only wide local excision is associated with prolonged survival.
 
Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review 289
C.J. Ma, S.F. Yang, C.C. Huang, C.Y. Chai, K.I. Cheng, E.M. Tsai, J.Y. Wang - Kaohsiung, TAIWAN
Extragenital MMMTs are rare and may be associated with synchronous gastrointestinal or gynecological malignancies.
 
Pelvic actinomycosis mimicking ovarian malignancy: three cases 294
S.E. Akhan,Y. Dogan, S. Akhan, A.C. Iyibozkurt, S. Topuz, O. Yalcin - Istanbul, TURKEY
Three cases of pelvic actinomycosis mimicking ovarian cancer are described. All cases had a history of IUD use.
 
A case of endometrial carcinoma arising in a 36-year-old woman with uterine atypical polypoid adenomyoma (APA) 298
K. Bakalianou, N. Salakos, C. Iavazzo, G. Paltoglou, K. Papadias, A. Kondi-Pafiti - Athens, GREECE
A case of endometrial carcinoma arising in a 36-year-old woman with atypical polypoid adenomyoma is presented.
 
Immature teratoma in pregnancy: a case report and literature review 300
A. Daponte, E. Kostopoulou, A. Zavos, H. Skentou, A. Kallitsaris, G. Koukoulis, I.E. Messinis - Larissa, GREECE
An immature Stage I teratoma was removed during pregnancy. Appropriate surgical staging enabled avoidance of chemotherapy despite the unexpected histological diagnosis.